selective SMARCA4 degrader
/ Dr. Reddy’s, Aurigene
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
Identification of first-in-class paralog selective SMARCA4 degraders for treatment of hematological and prostate malignancies
(AACR 2025)
- "Identified compounds have shown selective degradation of SMARCA4 over SMARCA2 in multiple cell lines. Few potent SMARCA4 selective degraders were optimized for pharmacokinetic properties and further evaluation of tolerability and efficacy in rodents is in progress."
Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • PTEN • SMARCA2 • SMARCA4
1 to 1
Of
1
Go to page
1